(thirdQuint)FIRSTx - A Study of Oral CXA-10 in Primary Focal Segmental Glomerulosclerosis (FSGS).

 This is a multicenter, open label, randomized study investigating two dose titration regimens of CXA-10 in subjects at least 18 years of age with primary FSGS.

 The study will be performed at approximately 20 study centers across the United States of America (USA).

 The recruitment period is anticipated to be up to approximately 12 months.

 Approximately 30 subjects will be randomized.

 Study participation for each subject will last up to 5 months.

 The study will consist of a screening period not to exceed 30 days (1 month), 90-day (3 month) treatment period, and an approximate 28-day (1 month) follow-up period after the last dose of study medication.

.

 FIRSTx - A Study of Oral CXA-10 in Primary Focal Segmental Glomerulosclerosis (FSGS)@highlight

This is a multicenter, open label, randomized study investigating two dose titration regimens of CXA-10 in subjects at least 18 years of age with primary FSGS.

 The study will be performed at approximately 20 study centers across the United States of America (USA).

 The recruitment period is anticipated to be up to approximately 12 months.

 Approximately 30 subjects will be randomized to ensure 26 subjects complete the study.

